Pembrolizumab (MK-3475) plus investigational agents in resectable non-small cell lung cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Trial Identifier:	3475-01E
Sponsor:	MSD
Start Date:	March 2025
Primary Completion Date:	November 2031
Study Completion Date:	February 2032
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary – English

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.